IMUX: Immunic, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 84.97
Enterprise Value ($M) 49.30
Book Value ($M) 18.43
Book Value / Share 0.20
Price / Book 4.61
NCAV ($M) 16.89
NCAV / Share 0.19
Price / NCAV 5.03

Profitability (mra)
Return on Invested Capital (ROIC) -5.17
Return on Assets (ROA) -0.96
Return on Equity (ROE) -1.20

Liquidity (mrq)
Quick Ratio 1.77
Current Ratio 1.77

Balance Sheet (mrq) ($M)
Current Assets 39.33
Assets 40.87
Liabilities 22.44
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -98.05
Net Income -100.51
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -84.77
Cash from Investing -0.26
Cash from Financing 74.54

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G/A Janus Henderson Group Plc 3.00 -47.27
02-14 13G/A Avidity Partners Management LP 9.90 0.37
02-12 13G/A Adage Capital Management, L.P. 1.55 -75.00
01-30 13G/A Vanguard Group Inc 4.35 -16.52
11-14 13G/A Rtw Investments, Lp 6.10 29.05

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 87,504 206,373 42.40
2025-04-16 111,530 351,690 31.71
2025-04-15 162,609 430,190 37.80
2025-04-14 82,545 366,300 22.53

(click for more detail)

Similar Companies
IDYA – IDEAYA Biosciences, Inc. IFRX – InflaRx N.V.
IGMS – IGM Biosciences, Inc. IMVT – Immunovant, Inc.
INBX – Inhibrx Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io